石药集团美洛昔康纳晶注射液破局而生

石药集团
Sep 23, 2025

前言疼痛管理是临床面临的重大挑战,现有镇痛方案常因药效短暂、需频繁给药或副作用明显等问题,难以满足术后镇痛需求。因此,长效、安全且便捷的镇痛药物成为临床迫切之需。美洛昔康纳晶注射液(Anjeso®)作为全球首款FDA长效静脉非甾体药物(NSAIDs),曾凭借纳米晶技术带来突破,却因商业原因一度退市,令人扼腕。但科学终将照亮现实——FDA对其价值的重申,为Anjeso®重回临床铺平道路。石药集团凭借...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10